Premium
Exosomes in tuberculosis: Still terra incognita?
Author(s) -
Hadifar Shima,
Fateh Abolfazl,
Yousefi Mohammad Hadi,
Siadat Seyed Davar,
Vaziri Farzam
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.27555
Subject(s) - tuberculosis , microvesicles , exosome , biomarker , medicine , immune system , pathogen , vaccination , immunology , biology , pathology , microrna , biochemistry , gene
Today, diagnosis, vaccination, and treatment of tuberculosis (TB) remain major clinical challenges. Therefore, an introduction of new diagnostic measures and biomarkers is necessary to improve infection control. The ideal biomarker for TB infection can be defined as a host or pathogen‐derived biomolecule, which is potent for identifying infection and determining its clinical stage. Exosomes, defined as cell‐derived nanovesicles released into biological fluids, are involved in cell–cell communication and immune modulation. These vesicles have emerged as a new platform for improving the clinical diagnosis and prognosis of different infectious diseases and cancers. The role of these nanovehicles, as alternative biomarkers for the improvement of TB diagnosis and treatment, has been demonstrated in a significant body of literature. In this review, we summarized recent progress in the clinical application of exosome‐based biomarkers in TB infection.